Genelux Corporation Announces Productive Type C Meeting with FDA
- Thursday, May 7, 2020, 7:19
- Business
- Add a comment
SAN DIEGO, May 7, 2020 /PRNewswire/ — Genelux Corporation, a privately-held, clinical-stage immunotherapy company, today announced the outcome of a Type C meeting with the U.S. Food and Drug Administration (FDA) held on May 6, 2020. The discussion focused on elements of the Company’s…
About the Author
adminasapcorp has written 41538 stories on this site.